Twitter Logo Youtube Circle Icon LinkedIn Icon

Co-Publishing weltweit

China Drug Registration Regulation - Public consultation on amendment closes - March 2014

January 2015 - Corporate & Commercial. Co-Publishing von Norton Rose Fulbright.

More articles by this firm.

In February 2014, the China Food and Drug Administration (“CFDA”) invited second-round comments from the public regarding proposed amendments to the China Drug Registration Regulations (“DRR”). One of the proposed amendments touches upon patent protection for drugs in China.